Co-Diagnostics Announced That It Submitted Its Co-DX PCR COVID-19 Test With Co-Dx PCR PRO Instrument For Review By The FDA For Emergency Use Authorization
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics has submitted its Co-DX PCR COVID-19 test and Co-Dx PCR PRO instrument for FDA Emergency Use Authorization. The platform aims to support point-of-care and at-home testing, with a development pipeline including tests for TB, HPV, and a multiplex respiratory panel for flu A/B, COVID-19, and RSV.
December 27, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Co-Diagnostics has submitted its Co-DX PCR COVID-19 test and Co-Dx PCR PRO instrument for FDA Emergency Use Authorization, potentially expanding its product offerings and market reach.
The submission for FDA Emergency Use Authorization is a significant step for Co-Diagnostics, indicating potential growth in its product line and market presence. If approved, it could lead to increased sales and market share, positively impacting the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100